BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.31 per share, missing estimates of -$1.15 ...
BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...
Hosted on MSN29d
Why BridgeBio Pharma (BBIO) Is Skyrocketing NowIn this article, we are going to take a look at where BridgeBio Pharma (NASDAQ:BBIO) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have ...
Feb. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases announced today ...
BridgeBio Pharma Inc (NASDAQ:BBIO) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 revenue is $3.48 million, and the earnings are expected to come in at ...
Shares of BridgeBio Pharma ticked up on Thursday after the company reported early but encouraging signs of demand for a drug it’s just begun selling for a deadly heart condition. “I am very ...
(RTTNews) - BridgeBio Pharma, Inc. (BBIO ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results